26th Annual International Lung Cancer Congress®

Breakfast and Non-CE Product Theater: A Novel Approach in Multi-lineage Myeloprotection for ES-SCLC Patients

Welcome, Introductions, and Presession Survey

Classical EGFR Mutations: How I Choose First-Line Therapy

Classical EGFR Mutations: Therapy After Acquired Resistance

Atypical EGFR Mutations

EGFR Exon 20 Mutations: mAbs and More?

Case-Based Panel Discussion

Unpacking c-Met and MET Alterations in NSCLC: Distinguishing Pathways to Precision Therapy (Spotlight CE Session)

Break

Updates on Radiation Techniques for Locally Advanced Disease and When to Reirradiate

Pathologic Considerations in Locally Advanced NSCLC

Pushing the Envelope in Locally Advanced Disease: Surgical Techniques

Role of the Interventional Pulmonologist in Locally Advanced Disease

Case-Based Panel Discussion in Locally Advanced NSCLC

Updates in Targeted Therapy for Locally Advanced NSCLC

Immunotherapy in Locally Advanced NSCLC: Latest Findings

Postsession Survey

Q&A/Panel Discussion

Lunch

Lunch and Non-CE OnLive® Seminar: ALK+ NSCLC in Focus: Leveraging the Latest Data to Guide Treatment

Lunch and Non-CE Product Theater: Innovative Therapy Options to Meet Diverse Patient Needs Across NSCLC

Presession Survey

Role of the Surgeon in Managing Oligometastases

Role of the Radiation Oncologist in Managing Oligometastases

Panel Discussion

Inaugural David R. Gandara, MD Keynote Lecture Introduction

Evolution of Molecular Profiling in Non-Small Cell Lung Cancer: Past, Present & Future

Q&A Session

Immunotherapy in SCLC (SOC in Limited and Extensive Disease)

Novel Approaches to Therapy in SCLC (Bispecifics, ADCs)

Multidisciplinary Case-Based Panel Discussion: SCLC

Molecular and Expression Testing in NSCLC: Who, When, and How?

HER2 (ADC/TKI)

BRAF

KRAS

Managing Brain Metastases in Oncogene-Driven Disease

Adjournment

Outdoor Welcome/Get-Acquainted Reception in the Lighthouse Courtyard

Coffee Talk™: Expert Perspectives on HER2-Targeted TKIs in Lung Cancer – Insights, Innovations, and Integration

Bringing IO Into the First Line: IO +/- Chemotherapy; Duration of Therapy

Management of Toxicities From Cancer Immunotherapy

What's New in Immunotherapy for Stage IV NSCLC

How to Manage Immunotherapy–Refractory NSCLC

Addressing Disparities in Lung Cancer

Panel Discussion: What Is Being Done at Your Center to Reduce Barriers to Clinical Trial Enrollment?

Breakfast and Non-CE OnLive® Seminar: PD-L1 Expression Across Histologies: Tailoring IO-Based Regimens for Squamous and Nonsquamous Advanced/Metastatic NSCLC

Innovative Approaches to Smoking Cessation

NTRK/NRG1

ROS1

Tumor Board: Mesothelioma and Thymic Malignancies

18th Annual Addario Keynote Lecture Introduction

Tackling the Global Burden of Lung Cancer

Lunch and Non-CE Product Theater: Evolving Strategies for Adults with Previously Treated Locally Advanced or Metastatic EGFRm NSCLC

Lunch and Non-CE Product Theater: First-Line Treatment of ALK+ mNSCLC: Clinical Case Study

Understanding ADCs: Targets, Linker, and Payload

Management of Toxicities From ADCs

How Do You Beat Taxanes? ADCs and Other Modalities

ADCs and Immunotherapy: Can We Achieve Synergy?

Expanding Screening Efforts in Lung Cancer

Multiomic and AI-Assisted Approaches in Localized NSCLC

Targeted Agents and ADCs in Early-Stage NSCLC–What's New?

Current Status of Immunotherapy in Early-Stage NSCLC